San Diego-based Cebix has closed a $30.9 million Series B venture capital financing round to fund Phase IIb development for the company's C-peptide replacement therapy Ersatta, which may become the first disease-modifying treatment for peripheral neuropathy in type 1 diabetes patients.
Several companies have sought regulatory approvals for drugs that reduce the pain of diabetic peripheral neuropathy, rather than develop therapies...